In p53-null orthotopic and ectopic models of murine HCC, the CTCE-decorated nanocarriers combined with anti-PD-1 therapy enabled global reprogramming of the immune TME, leading to improved tumor inhibition effects compared to individual therapy alone. The gene discussed is TP53; the disease is hepatocellular carcinoma.